The Emerging Role of Oxaliplatin in the Treatment of Gastric Cancer

References

• Coleman MP, Gatta G, Verdecchia A, et al., and EURO-CARE Working Group. EUROCARE -3 summary: cancer sur-vival in Europe at the end of the 20th century. Ann Oncol 2003;14 (Suppl 5):V128–V149.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333: 32–41.
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric car-cinoma patients treated with gastrectomy. Cancer 1998; 88: 921–932.
   Google Scholar
• Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer inci-dence and survival in four continents. Eur J Cancer 2003; 39: 1603–1609.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Van Cutsem E. The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. Corectal Dis 2003;5(Suppl 3):36–44.
   PubMedGoogle Scholar
• Haller DG. Recent updates in the clinical use of plat-inum compounds for the treatment of gastrointestinal cancers. Semin Oncol 2004; 31 (6 Suppl 14): 10-16.
   Google Scholar
• Hoff PM, Fuchs CS. The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas (Review). Semin Oncol 2003; 30 (4 Suppl 15):54-61.
   Google Scholar
• Dickinson JLB, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 2004; 16: 255–63.
   PubMed Web of Science ®Google Scholar
• Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric Cancer. Crit Rev Oncol Hematol 2005; 54: 209–241.
   PubMed Web of Science ®Google Scholar
• Webb A, Cunnigham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus flu-orouracil, doxorubicin, and methotrexate in advanced esopha-gogastric cancer. J Clin Oncol 1997; 15: 261–267.
   PubMed Web of Science ®Google Scholar
• Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin and protract-ed venous infusion fluorouracil (PVI 5-FU) with Epirubicin, cis-platin and PVI 5-FU in advanced esophagogastric cancer. JCO 2002; 20: 1996–2004.
   Google Scholar
• Cunningham D, Allum WH, Stenning SP, Weden S, for the NCRI Upper GI Cancer Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 2005; 23:abstract 4001.
   Google Scholar
• Ajani JA. Docetaxel for gastric and esophageal carcino-mas. Oncology (Huntingt) 2002; 16: 89–96.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Baker J, Pjsters PW, et al. CPT-11 plus cis-platin in patients with advanced, untreated gastric or gastro-esophageal junction carcinoma: results of a phase II study. Cancer 2002; 94: 641–646.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Van Cutsem E, Moiseyenko V, et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003,22: abstract 999.
   Google Scholar
• Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epiru-bicin, cisplatin, and fluorouracil for advanced gastric adenocar-cinoma: a randomized phase II study. J Clin Oncol 2005; 23: 494–501.
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C et al. Randomized phase III trial of irinotecan (CPT-11) + 5-FU/folinic acid (FA) vs CDDP + %-FU in 1st-line advanced gastric cancer patients. Proc Am Soc Clin Oncol 2005; 23:abstract 4003.
   Google Scholar
• Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicentre phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004; 22: 4319-4328.
   Google Scholar
• Souglakos J, Syrigos K, Potamianou A, et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 2004; 15: 1204–1209.
   Google Scholar
• Raymond E, Faivre S, Woynarowsky JM, Chaney Sc. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25: 4–12.
   PubMed Web of Science ®Google Scholar
• Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluo-rouracil: clinical experience in patients with advanced colorec-tal cancer. Semin Oncol 1998; 25: 32–39.
   PubMed Web of Science ®Google Scholar
• Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053–1071.
   PubMed Web of Science ®Google Scholar
• Eriguchi M, Nonaka Y, Yanagie H, Yoshizaki I, Takeda Y, Sekiguchi M. A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against estab-lished human gastric cancer cell lines. Biomed Pharmacother 2003; 57: 412–415.
   PubMed Web of Science ®Google Scholar
• Trojan J, Kim SZ, Engels K, Kriener S, Mitrou PS, Chow KU. In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer. Anti-Cancer Drugs 2005; 16: 87–91.
   PubMed Web of Science ®Google Scholar
• Lin WL, Li DG, Chen Q, Lu HM. Clinical and experi-mental study of oxaliplatin in treating human gastric carcino-ma. World J Gastroenterol 2004; 10: 2911–2915.
   PubMed Web of Science ®Google Scholar
• Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Martyn M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299–303.
   PubMed Web of Science ®Google Scholar
• Louvet C, Andrê T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543–4548.
   PubMed Web of Science ®Google Scholar
• Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucov-orin for advanced colorectal cancer. Clin Cancer Res 2004; 10: 4055-4061.
   Google Scholar
• Jin M, Chen Q, Cheng FQ, et al. Oxaliplatin (O)(A) in combination with LV5FU2 in Chinese patients with advanced gastric cancer (ACC). Proc Am Soc Clin Oncol 2002; 21: abstract 558.
   Google Scholar
• Mauer AM, Kraut EH, Rudin CM, et al. Phase II study of oxaliplatin (OX), fluorouracil (FU) and leucovorin (LV) in metastatic carcinoma of the esophagus/gastric cardia. Proc Am Soc Clin Oncol 2002; 21: abstract 554.
   Google Scholar
• Bang YJ, Kang YK, Kang WK, et al. Phase II study of oxaliplatin, 5-fluorouracil and folinic acid in recurrent or metastatic gastric cancer. Proc Am Soc Clin Oncol 2002; 21: abstract 2249.
   Google Scholar
• Ji JF, Yu Z, Zhong XN, et al. Oxaliplatin-based regi-men as neoadjuvant chemotherapy for Chinese patients with advanced gastric cancer: preliminary results of a phase II study. Proc Am Soc Clin Oncol 2004; 23: abstract 4184.
   Google Scholar
• Chen JS, Huang JS, Yang TS, et al. Phase I dosing-escalating study of oxaliplatin in combination with oral tegafur-uracil/leucovorin in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2004; 23: abstract 4266.
   Google Scholar
• Cavanna L, Zaniboni A, Artioli F, et al. Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC). Proc Am Soc Clin Oncol 2004; 23: abstract 4068.
   Google Scholar
• Chao Y, Chang CJ, Chen LT, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluo-rouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91: 453–458.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658–663.
   PubMed Web of Science ®Google Scholar
• Pirovano MM, Quinte A, Romanelli A, et al. Chronomodulated delivery schedule of oxaliplatin, 5-fluo-rouracil and folinic acid as first line treatment for metastatic gastric cancer: toxicity and dose intensity data of a pilot study. Proc Am Soc Clin Oncol 2003; 22: abstract 1214.
   Google Scholar
• Petrovic Z, Tarabar D, Doder R, Peric A. Oxaliplatin (L-OHP) and capecitabine (X) as second line chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2003; 22: abstract 1199.
   Google Scholar
• Chen JS, Huang JS, Yang TS, et al. Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. Anti-Cancer Drugs 2005; 16: 47–51.
   PubMed Web of Science ®Google Scholar
• Santini D, Graziano F, Catalano V, et al. Weekly oxali-platin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric can-cer (ACC). Proc Am Soc Clin Oncol 2004; 23: abstract 4237.
   Google Scholar
• lop A, Bonura S, Manfredi A, Artioli F. Combination of oxaliplatin, 5-fluorouracil and folinic acid in advanced metasta-tic gastric carcinoma. Proc Am Soc Clin Ocol 2004; 23; abstract 60.
   Web of Science ®Google Scholar
• De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-Fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 26: (Epub ahead of print)
   Google Scholar
• Al-Batran SE, Stohlmacher J, Probst S et al. Fluorouracil, leucovorin and oxaliplatin (FLO) as a first line therapy for patients with advanced gastric cancer: First interim analysis of a randomized multicenter phase II study. Proc Am Soc Clin Oncol 2005; 23: abstract 4015.
   Google Scholar
• Duyster J, Lorenzen S, Kullmann F et al. Oxaliplatin plus 5-FU/folinic acid (FUFOX regimen) in first-line metastatic gastric cancer (MCC). Results of the multicenter phase II STO-MOX trial. Proc Am Soc Clin Oncol 2005; 23: abstract 4016.
   Google Scholar
• Catalano V, Graziano F, Salvagni S, et al. Lack of resistance to oxaliplatin (L-OHP)-based chemotherapy in patients (pts) with advanced gastric cancer previously treated with cisplatin-containing regimens: preliminary results of a phase II study. Proc Am Soc Clin Oncol 2002; 21: abstract 2200.
   Google Scholar
• Johnson-Barque EJ. Raltitrexed plus oxaliplatin and leu-covorin modulated continuous 5-FU infusion (ROLF) in metastatic (MCC) and local advanced (LAGC) gastrointestinal cancer. A phase VII study. Proc Am Soc Clin Oncol 2004; 23: abstract 4627.
   Google Scholar
• Chac6n JI, Felift J, Saenz JAG, et al. Oxaliplatin (Ox) and raltitrexed (Ral) as first line treatment for locally advanced and metastatic gastric adenocarcinoma: results of an ONCO-PAZ phase II trial (OPHA OL141). Proc Am Soc Clin Oncol 2004; 23: abstract 4213.
   Google Scholar
• Pan HM, Zhu N, Lou F, et al. A phase II study of oxaliplatin with ELF regimen in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2004; 23: abstract 4206.
   Google Scholar
• Tebbutt N, Norman A, Cunningham D, et al. Randomised, multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in advanced oesophago-gastric cancer; interim analysis. Proc Am Soc Clin Oncol 2002; 21: abstract 523.
   Google Scholar
• Sumpter KA, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analysis in a random-ized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92: 1976–83.
   PubMed Web of Science ®Google Scholar
• Erlichman C, Boerner S, Kaufmann SH. Interaction of oxaliplatin with the topoisomerase I inhibitors topotecan and SN-38 (ENG). Ann Oncol 1998; 9 (Suppl 2): 25S.
   PubMed Web of Science ®Google Scholar
• Zeghari-Squalli N, Misset JL, Cvitkovic E et al. Mechanism of the in vitro synergism between SN38 and oxali-platin (ENG). Proc Am Assoc Cancer Res 1997; 38: 3 (abstract).
   Google Scholar
• Bissery MC, Vrignaud P, Lavelle F. In vivo evaluation of the irinotecan-oxaliplatin combination. Proc Am Assoc Cancer Res 1997; 39: 526–527 (abstract).
   Google Scholar
• Woe11 E, Eisterer W, Hilbe W, et al. Oxaliplatin and irinotecan in advanced gastric cancer. A pilot trial. Proc Am Soc Clin Oncol 2003; 22: abstract 1299.
   Google Scholar
• Lordick F, Lorenzen S, Stollfuss J, et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gas-tric cancer. Br J Cancer 2005; 93: 190–4.
   Google Scholar
• Correale P, Fulfaro F, Marsili S, et al. Gemcitabine plus oxaliplatin,folinic acid and 5-fluorouracil (FOLFOX-4)in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2005, July 23 (Epub ahead of print).
   Google Scholar